- Ticker
- ACTI.ST
- Price
- 0.50
- Stock movement up
- +0.01 (1.61%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 182.35M
- Ent value
- 170.35M
- Price/Sales
- -
- Price/Book
- 9.03
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -2.79%
- 1 year return
- -27.35%
- 3 year return
- -26.87%
- 5 year return
- -26.11%
- 10 year return
- -28.73%
Last updated: 2024-07-23
DIVIDENDS
ACTI.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 9.03 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 361.81M |
| EPS (TTM) | -0.12 |
| FCF per share (TTM) | -0.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -1.60M |
| Operating income (TTM) | -45.40M |
| Net income (TTM) | -44.80M |
| EPS (TTM) | -0.12 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 25.40M |
| Net receivables | 3.30M |
| Total current assets | 28.60M |
| Goodwill | 0.00 |
| Intangible assets | 200.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 33.60M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 2.60M |
| Total current liabilities | 10.80M |
| Total liabilities | 13.40M |
| Shareholder's equity | 20.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -45.10M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -45.10M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -221.78% |
| Return on Assets | -133.33% |
| Return on Invested Capital | -221.78% |
| Cash Return on Invested Capital | -223.27% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.51 |
| Daily high | 0.51 |
| Daily low | 0.50 |
| Daily Volume | 91K |
| All-time high | 289.27 |
| 1y analyst estimate | 1.50 |
| Beta | 0.34 |
| EPS (TTM) | -0.12 |
| Dividend per share | - |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 22 Aug 2024 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -99.83% | -1.81% |
| Highest price drop | -99.85% | -56.47% |
| Date of highest drop | 21 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -91.86% | -11.26% |
| Avg time to new high | 6897 days | 12 days |
| Max time to new high | 6896 days | 1805 days |
COMPANY DETAILS
Marketcap
182.35M
Marketcap category
Small-cap
Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Employees
8
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found